CAS 14271-05-7

Mesilato de dihidro-α-ergocriptina

Descripción:

Mesilato de dihidro-α-ergocriptina es un derivado semisintético de los alcaloides del cornezuelo, utilizado principalmente por sus propiedades farmacológicas. Se caracteriza por su capacidad para actuar como un agonista del receptor de dopamina, lo que lo hace relevante en el tratamiento de condiciones como la enfermedad de Parkinson y otros trastornos del movimiento. La sustancia generalmente aparece como un polvo cristalino blanco a blanco sucio y es soluble en disolventes orgánicos, con solubilidad limitada en agua. Su estructura química incluye un complejo sistema de anillos tetracíclicos, que es común entre los derivados del cornezuelo, contribuyendo a su actividad biológica. Mesilato de dihidro-α-ergocriptina se administra a menudo en forma de su sal mesilato, mejorando su estabilidad y biodisponibilidad. Al igual que muchos compuestos farmacológicamente activos, puede presentar efectos secundarios, y su uso debe ser monitoreado en entornos clínicos. Las condiciones adecuadas de manejo y almacenamiento son esenciales para mantener su eficacia y perfil de seguridad.

Fórmula: C₃₂H₄₃N₅O₅·CH₄O₃S

InChI: InChI=1S/C32H43N5O5.CH4O3S/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20;1-5(2,3)4/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38);1H3,(H,2,3,4)/t20-,22-,24-,25+,26+,31-,32+;/m1./s1

Clave InChI: InChIKey=TZGKQIBPZOZAKF-PJLVGBPESA-N

SMILES: O[C@@]12N([C@@H](CC(C)C)C(=O)N3[C@]1(CCC3)[H])C(=O)[C@@](NC(=O)[C@@H]4C[C@@]5(C=6C=7C(C[C@]5(N(C)C4)[H])=CNC7C=CC6)[H])([C@@H](C)C)O2.S(C)(=O)(=O)O

Sinónimos:

• (5'Alpha,10Alpha)-12'-Hydroxy-5'-(2-Methylpropyl)-3',6',18-Trioxo-2'-(Propan-2-Yl)-9,10-Dihydroergotaman Methanesulfonate (1:1)
• 8H-Oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine, ergotaman-3′,6′,18-trione deriv.
• 9,10-Dihydroergocryptine methanesulfonate
• 9,10alpha-Dihydro-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate
• Ccris 6730
• Cripar
• Dihydro-alpha-ergocryptine mesylate
• Dihydro-α-ergocryptine mesylate
• Ergocryptine, dihydro-, methanesulfonate
• Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha,10alpha)-, monomethanesulfonate (salt)
• Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-, (5α,10α)-, methanesulfonate (1:1)
• Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-, (5′α,10α)-, monomethanesulfonate (salt)
• Indolo[4,3-fg]quinoline, ergotaman-3′,6′,18-trione deriv.
• Unii-Z4I7Bu58Dn
• alpha-Dihydroergocryptine

Dihydro-α-ergocryptine mesylate

CAS: 14271-05-7

Dihydro-alpha-ergocryptine mesylate is a drug that inhibits the effects of ergotamine and other drugs. It is used in animals to treat drug reactions, such as those caused by morphine and penicillin. Dihydro-alpha-ergocryptine mesylate can be detected in urine samples for up to 72 hours after administration. The pharmacokinetic properties of this drug are not well understood, but there is a linear relationship between dose and plasma concentration. The clinical response to dihydro-alpha-ergocryptine mesylate has been shown to be dose dependent. This drug also has dopaminergic properties, which may be due to its ability to bind with dopamine receptors in the central nervous system. There are several symptoms that may be related to taking this drug, including drowsiness or fatigue, nausea or vomiting, dry mouth, muscle spasms, and involuntary shaking of a part of the body (tremor).

Fórmula: C₃₃H₄₇N₅O₈S

Pureza: Min. 95%

Peso molecular: 673.82 g/mol

Ref: 3D-FD176343